Lilly once again beats expectations as tirzepatide accounts for 64% of revenue
Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. Lilly also once again raised its full-year revenue guidance to between $85 billion and $87 ...
August 5, 2026 07:21 AM EDT PharmaGLP-1 drugs Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue Kyle LaHucik Biotech Correspondent Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts’ estimates. Lilly also once again raised … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that